DMD #3392R INTRODUCTION
Cytochrome P450 2E1 (CYP2E1) is an enzyme of the CYP2 family of cytochrome P450 heme enzymes known to be responsible for metabolic activation of many low molecular weight compounds suspected to act as chemical carcinogens. It is a major catalyst of the oxidation of benzene, styrene, carbon tetrachloride, chloroform, dichlormethane and other chlorderivatives of methane and ethane, of vinyl chloride, and is known to take part in metabolic activation of nitrosamines (Guengerich et al., 1991) . CYP2E1 metabolizes volatile anesthetics (halothane, enflurane) and some drugs of relatively small molecules as acetaminophen and isoniazid (Lieber, 1997) . Its physiological role is apparently connected with regulation of energy balance and of the lipid metabolism as it is induced by starvation and diabetes (Lieber, 1997) . CYP2E1 is known to metabolize ethanol; it is also inducible by ethanol and by some endogenous compounds such as acetone. CYP2E1 is expressed in human fetus early in development which indicates its importance for developing human organism (Johnsrud et al., 2003) . It is one of the major hepatic CYP enzymes, however, it has been also detected in significant levels in human esophagus, kidney, lung (Lieber, 1997) and brain (Upadhya et al., 2000) .
Pig and minipig liver microsomal CYP enzymes have been studied in more detail recently.
CYP enzymes were shown to be involved in metabolism of veterinary drugs (Monshouwer et al, 1998) . Moreover, their properties are intensively studied as CYP activities belong to important functional characteristics of minipig or pig livers (Anzenbacher et al., 1998 , Skaanild and Friis, 1999 , Soucek et al., 2001 Myers et al. (2001) have investigated the properties of the market weight swine CYP enzymes in liver microsomes and in the S10 fraction by Western blot; also, enzyme activities specific for individual CYP enzymes have been determined in subcellular preparations. Interest in pig or minipig hepatocytes and CYPs increased over the last few years as they seem to be suitable models in experimental pharmacology (Václavíková et al., 2004) and, moreover, pig hepatocytes are possibly intended also for xenotherapy or for construction of bioartificial liver supporting devices (Desille et al., 1999 , Donato et al., 1999 , Couzin, 2002 .
To date, only one successful attempt to obtain partially purified minipig liver microsomal drug metabolizing CYP enzymes has been published. Soucek et al. (2001) 
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bolite and that the minipig CYP2A enzyme metabolizes coumarin, a characteristic substrate of the human CYP2A6. To get more detailed information on individual CYP enzymes from pig or minipig, purified CYP2E1 has been isolated from minipig liver microsomes for the first time and its structural and enzymological characteristics are described and compared with properties of the human orthologous form.
MATERIALS AND METHODS
Chemicals. All reagents and chemicals were reagent grade and were obtained from Sigma Aldrich (Prague, CZ) if not stated otherwise. Chemiluminiscence kit for Western blotting (Immun Star) was purchased from Bio Rad (Hercules, CA) and the nitrocellulose membrane was from Amersham Biosciences (Little Chalfont, GB). Goat anti human CYP2E1 antibody was from Daichi Pure Chemicals (Tokyo, Japan). BCA protein determination kit was obtained from Pierce (Rockford, IL). Human NADPH:cytochrome P450 oxidoreductase (CYP reductase) was purchased from Sigma, minipig enzyme was prepared from fractions obtained during the first step of minipig CYP isolation by the method of Soucek et al. (2001) . CYP reductase was then isolated by affinity chromatography (Yasukochi and Masters, 1976) . Medicine, Brno, CZ, 25-30 kg body weight, male castrates, N=5, age 6 months, approved by local and national Ethical Commissions) by a standard procedure (Lake, 1990) . Microsomal fraction was solubilized by cholate and applied onto the octylamino Sepharose CL-4B column. The isolation method generally followed this one described earlier (Soucek et al., 2001) RNA quality and quantity was assessed by UV-VIS spectrophotometry and agarose gel electrophoresis. cDNA was then synthesized using 1 µ g of total RNA with help of kit purchased from MBI Fermentas (Vilnius, LT). Minipig cDNA was amplified by PCR with forward, 5´-catatggctgctttaggtattactgttgctttattagtgtggttg-3´ and reverse, 5´-gtcgactcagtgatggtgatggtgatgcacttgtgagcgggg-3´ primers designed using the known pig CYP2E1 sequence (GenBank AB052259). First eleven codons of forward primer were changed (the only primary structure change created was second amino acid to Ala) to prevent unfavorable secondary structure formation during subsequent protein expression trials, and the reverse primer contained a 6-His tag sequence for facile purification of expressed protein.
Conditions for PCR amplification in GeneAmp 9700 thermocycler (Applied Biosystems,
Foster City, CA) were: 3min denaturation at 94°C, 10 cycles of 30sec at 94°C, touch down annealing for 30sec at 60 gradually decreasing to 50°C, 2min at 72°C followed by 25 cycles of 30sec at 94°C, 30sec at 65°C, 2min at 72°C with 1.5mM MgCl 2 in the general reaction mixture. The resulting PCR product was further amplified in nested PCR reaction containing forward, 5´-GGGGACAAGTTTGTACAAAAAAGCAGGCTaccatatggctgctttaggtatt-3´ and reverse, 5´-GGGGACCACTTTGTACAAGAAAGCTGGGTagtcgactcagtgatg-3´ primers.
Both primers carried sequence compatible with the specific recombination sites of Gateway system (sequences in capital letters) for direct cloning and expression in Escherichia coli (Invitrogen). Forward primer also contained NdeI restrictrion site and reverse primer SalI restriction site (both positions underlined) for subcloning into expression vector pCW´ previously used for expression of human CYPs (Sandhu et al. 1993) . Conditions of PCR cycling were: 3min denaturation at 94°C, 10 cycles of 30sec at 94°C, touch down annealing for 30sec at 60 gradually decreasing to 50°C, 2min at 72°C followed by 25 cycles of 30sec at 94°C, 2min30sec at 72°C with 2.5mM MgCl 2 in the general reaction mix. For both PCR reactions Platinum Pfx polymerase with proofreading activity was used (Invitrogen). Minipig CYP2E1 coding sequence was then cloned into pDONR201 plasmid of the Gateway according to protocol supplied with the product (Invitrogen 
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For ligation, T4 DNA ligase (New England Biolabs) and For transformation Maximum
Efficiency DH5α E. coli Competent Cells (Invitrogen) were used following directions suggested by the producers. For DNA sequencing, fragment bearing the CYP2E1 clone with adjacent pCW´ sequences was amplified using forward, 5´-atcgatgcttaggaggtcat-3´ and reverse, 5´-aggccctttcgtcttcaa-3´ primers and cycling conditions: 3min denaturation at 94°C, 10 cycles of 30sec at 94°C, touch down annealing for 30sec at 60 gradually decreasing to 50°C, 2min at 72°C followed by 25 cycles of 30sec at 94°C, 30sec at 55°C, 2min at 72°C with 1.5mM MgCl 2 in the general reaction mixture. Product was then purified from 1% agarose gel by Perfectprep® Gel Cleanup Kit (Eppendorf, Hamburg, Germany) and processed for sequencing using BigDye Terminator Kit v3.1 (Applied Biosystems) according to manufacturer's recommendations. Primers used for sequencing PCR were as follows: 5´- Enzyme assays. Chlorzoxazone 6-hydroxylating activity of CYP2E1 preparations in microsomes as well as in the reconstituted systems was determined according to Lucas et al. (1996) . Hydroxylation of p-nitrophenol was assessed by the method of Tassaneeyakul et al. (1993) . For both methods, an HPLC system of Shimadzu (Tokyo, Japan) Class VP was used.
The experiments were routinely performed in quadruplicate. Reconstitution systems were prepared as described by Shimada and Yamazaki (1998) using the respective reductases.
Inhibition of chlorzoxazone 6-hydroxylation by diethyldithiocarbamate was studied with microsomal and reconstitution systems and the K i values were determined as averages from
Dixon plots with three substrate concentrations used (corresponding to 0.5K M , K M and 2K M ) .
Parameters of enzyme kinetics were obtained using LSW Data Analysis software (www.mdli.com) and with Sigma Plot 8.0.2 (SPSS, Chicago, IL).
This article has not been copyedited and formatted. The final version may differ from this version. 
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CYP2E1 structure
Minipig CYP2E1 has been purified from liver microsomes to homogeneity (Fig. 1) . The protein has been clearly recognized by commercial goat antibodies against human CYP2E1 by Western blot.
To confirm the identity of this enzyme, primary structure has been determined. As the preliminary N-terminal sequencing experiments have confirmed the identity of the published pig (GenBank Accession No AB000885) and minipig CYP2E1 N-terminal sequences, it was possible to continue in obtaining the cDNA clone using the primers derived from the data for the pig enzyme. Sequencing of the cDNA has yielded a result published in the Gen Bank (Accession No AY581116).
The primary structures of minipig and pig CYP2E1 are identical with one exception: in position 346, there is an aspartic acid residue in the minipig enzyme contrary to valine in the pig protein. Interestingly, this minor change makes the minipig enzyme more similar to the human protein as the corresponding amino acid residue in the human protein is the glutamic acid. The pig or minipig protein is comprised of 496 amino acid residues; the human enzyme is two residues shorter. The minipig (or pig) CYP2E1 exhibits 79.6% primary sequence identity with human counterpart. The most remarkable difference in the primary structure of (mini)pig and human CYP2E1 is located close to the substrate recognition site region I (Gotoh, 1992). Here, two basic amino acids (His 92 and Asn 95) are present in mini(pig) CYP2E1 instead of two aspartic acid residues. Similarly, at the beginning of the F helix (and of the substrate recognition site 2), there is a basic lysine residue in the minipig and pig enzyme (Lys194) whereas a glutamic acid residue is present in the human CYP2E1. The differences in the primary structure of the (mini)pig enzyme do not include the key amino acid residues predicted to interact with a prototypic substrate chlorzoxazone in the substrate binding site of human CYP2E1 according to Park and Harris (2003) . For p-nitrophenol (another CYP2E1 substrate) bound in the active site of a human CYP2E1 model (Park and Harris, 2003) , the respective amino acid changes are merely conservative (V364L, P213G, G479A). Also, the model of CYP2E1 active site constructed on the basis of CYP2C5 (Lewis et al., 2003) exhibits the same amino acid residues in the active site in the human and minipig CYP2E1 enzyme.
Enzyme activities
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The relatively high degree of homology between primary structure of human CYP2E1 and orthologous enzymes from other mammalian species is reflected in similarity also in substrate specificity although some inter-species differences exist (e.g. in metabolism of butadiene) (Lewis et al., 1997) . We have investigated in detail enzyme kinetics of chlorzoxazone 6-hydroxylation and of p-nitrophenol hydroxylation in minipig liver microsomal fraction as well as in the reconstituted system with CYP2E1 and CYP reductase from minipig. Human liver microsomal samples and reconstituted system with human CYP2E1 and CYP reductase were used for comparison. Inhibition of CYP2E1 activities by diethyldithiocarbamate, typical inhibitor of CYP2E1 of human origin as well as of other species (Court et al., 1997) , was also investigated.
Results obtained with both prototypic substrates are displayed in the respective Tables.
In Table 1 , data for enzyme kinetics of chlorzoxazone hydroxylation in liver microsomal fraction and in reconstituted systems of both species (human and minipig) are shown. Data obtained with another substrate, p-nitrophenol, are displayed in Table 2 . The K M values for both substrates in the microsomal fraction and in the reconstituted system indicate lower affinity of the minipig enzyme; this is apparently true when also the V max /K M ratio (often taken as a measure of enzyme specificity) is considered. With the exception of the V max for pnitrophenol hydroxylation in the system reconstituted with minipig CYP2E1, data for minipig CYP2E1 show the differences lower than one order of magnitude (approximately four times higher K M and four times lower V max ) when compared with these for the respective human counterparts. The differences observed may be ascribed to changes in the polarity (or even reversals in the polarity) of amino acid residues in the minipig enzyme observed in the vicinity of the "substrate recognition sites" (see the preceding paragraph). However, the data conclusively document the ability of minipig enzyme to metabolize chlorzoxazone as well as p-nitrophenol at rates comparable to the human CYP2E1.
Inhibition of CYP2E1 activities by diethyldithiocarbamate (DEDC), although not strictly specific to this enzyme in man as well as in other species (Bogaards et al., 2000 , Sai et al., 2000 , is another commonly used probe of similarity of the human and of the minipig enzyme.
In this work, DEDC has been shown to inhibit chlorzoxazone 6-hydroxylation both in human 
the results for the reconstituted systems with only CYP2E1 present may indicate lower specificity of minipig CYP2E1for this inhibitor.
DISCUSSION
The results presented were obtained both with microsomal fraction and with the reconstituted systems thus answering to the principal question raised by Myers et al. (2001) whether the pig or minipig CYP2E1 is able to convert the prototypical human CYP2E1 substrates to the respective metabolites. Interestingly, specificity of the minipig enzyme corresponds to the properties of the human form: In humans, chlorzoxazone may be also converted (however, less effectively) to its 6-hydroxy metabolite also by CYP1A1 (Carriere et al., 1993) as well as by CYP3A enzymes (Gorski et al., 1997) . In line with this fact, there is in the minipig probably a contribution also from the CYP3A (Madden et al., 1998) as well as by the CYP1A enzymes to the metabolism of chlorzoxazone (Bogaards et al., 2000) in the microsomal preparations. Second substrate, p-nitrophenol, is known to be metabolized by CYP2E1 as well as (with lower turnover number) by CYP3A enzymes in man (Zerilli et al, 1997) . Most recent results indicate an involvement of CYP2A6 and possibly also of a CYP2C19 enzymes in this reaction (Monostory et al., 2004) . However, this activity is still recognized as the standard one for a CYP2E1 enzyme (Chang et al., 1998) ; hence, it should be tested with any new CYP2E1 species. The results presented here confirm the role of minipig CYP2E1 in this reaction ( Table 2) .
Comparison of CYP2E1 of minipig and of other species
CYP2E1 is one of the most conserved CYP enzymes according to the primary structure exhibiting nearly 80% sequence identity across species (Guengerich, 1997) . High sequence similarity corresponds to similar catalytic properties of CYP2E1 enzymes of various origin (Chauret et al., 1997; Court et al., 1997; Bogaards et al., 2000; Zuber et al., 2002) .
Comparison of catalytic rates is however difficult as the enzyme velocity is often expressed relative to protein instead to the more specific P450 content. Literature data seem to indicate a species-conserved mechanism for oxidative biotransformation by CYP2E1 (Court et al., 1997) . In this respect, minipig is apparently not an exception. In our hands, the K M values for 6-hydroxylation of chlorzxazone in liver microsomal fraction ranged from 40 µM (human) This article has not been copyedited and formatted. The final version may differ from this version. 
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to 201 µM (pig) and for p-nitrophenol hydroxylation from 30 µM (dog) to 121 µM (minipig) (Anzenbacherová et al., 2004) . Molecular mechanisms of induction of CYP2E1 in various species may however differ -e.g., β-naphthoflavone, a prototypical inducer of CYP1A, has been shown to induce also the CYP2E1 form in the dog (Jayyosi et al., 1996) . On the other hand, the CYP2E1 enzyme activities seem to be comparable in most of the species used in experimental pharmacology and toxicology hence allowing for successful modeling drug metabolism by CYP2E1 in man.
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